AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16281887 — intervention group
Group type: EXPERIMENTAL
Intervention: Volunteers
Number of subjects: 12866
Study 16281887 — intervention group
Group type: COMPARATOR
Intervention: Men excluded for presence of disease
Number of subjects: 12866
Study 16281887 — intervention group
Group type: COMPARATOR
Intervention: Men excluded with characteristics likely to interfere with adherence
Number of subjects: 12866
Study 11427330 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rizatriptan 5 mg
Number of subjects: 792
Study 11427330 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sumatriptan 50 mg
Number of subjects: 792
Study 11427330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 792
Study 11427330 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Analog Scale (VAS)
Number of subjects: 792
Study 11427330 — intervention group
Group type: EXPERIMENTAL
Intervention: Categorical Four-Grade Scale (4GS)
Number of subjects: 792
Study 11427330 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan and Sumatriptan
Number of subjects: 792
Study 11427330 — intervention group
Group type: EXPERIMENTAL
Intervention: VAS and 4GS scores
Number of subjects: 792
Study 11427330 — intervention group
Group type: EXPERIMENTAL
Intervention: VAS
Number of subjects: 792
Study 9727571 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir
Number of subjects: 1090
Study 11271338 — intervention group
Group type: EXPERIMENTAL
Intervention: FK 506
Number of subjects: 540
Study 11271338 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin
Number of subjects: 540
Study 2140663 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 2 mg cyproterone acetate (CPA) with 0.035 mg ethinyl estradiol (EE) (Diane 35)
Number of subjects: 162
Study 2140663 — intervention group
Group type: COMPARATOR
Intervention: Combination of 0.150 mg desogestrel (DG) with 0.03 mg ethinyl estradiol (EE) (Marvelon)
Number of subjects: 162
Study 301797 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal Mammary Artery Graft (IMAG)
Number of subjects: 74
Study 301797 — intervention group
Group type: COMPARATOR
Intervention: Saphenous Vein Bypass Graft (SVBG)
Number of subjects: 74
Study 31187238 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised intensive vestibular rehabilitation with visual biofeedback (postoperative rehabilitation program)
Number of subjects: 52
Study 31187238 — intervention group
Group type: COMPARATOR
Intervention: Prehabilitation with intratympanic application of gentamicin
Number of subjects: 52
Study 27402501 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthetist-directed sedation (ADS)
Number of subjects: 1171
Study 27402501 — intervention group
Group type: COMPARATOR
Intervention: Gastroenterologist-directed sedation (GDS)
Number of subjects: 1171
Study 25938614 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month intensive meditation retreat
Number of subjects: 60
Study 25938614 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 60
Study 24100786 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (10 mg)
Number of subjects: 15
Study 24100786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 21757515 — intervention group
Group type: EXPERIMENTAL
Intervention: 3T MR imaging (PD sequence)
Number of subjects: 26
Study 21757515 — intervention group
Group type: EXPERIMENTAL
Intervention: 3T MR imaging (GM sequence)
Number of subjects: 26
Study 21757515 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of LGN height and volume with clinical glaucoma stage
Number of subjects: 26
Study 19368512 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical vitamin B(12)
Number of subjects: 21
Study 19368512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 17516069 — intervention group
Group type: EXPERIMENTAL
Intervention: Milataxel (35 mg/m², administered intravenously every 3 weeks)
Number of subjects: 44
Study 15477049 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal 0.5% bupivacaine 7.5 mg with saline 1 mL (group B)
Number of subjects: 45
Study 15477049 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal 0.5% bupivacaine 7.5 mg with fentanyl 10 microg (group Bf10)
Number of subjects: 45
Study 15477049 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal 0.5% bupivacaine 7.5 mg with fentanyl 20 microg (group Bf20)
Number of subjects: 45
Study 11926203 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of ascorbic acid (AA) daily for four weeks
Number of subjects: 16
Study 11926203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 9716147 — intervention group
Group type: EXPERIMENTAL
Intervention: aPCR-tissue factor-based assay
Number of subjects: 82
Study 9716147 — intervention group
Group type: EXPERIMENTAL
Intervention: aPCR-dRVVT-based assay
Number of subjects: 82
Study 9716147 — intervention group
Group type: EXPERIMENTAL
Intervention: Both assays (when negative)
Number of subjects: 82
Study 9716147 — intervention group
Group type: COMPARATOR
Intervention: Polymerase chain reaction analysis
Number of subjects: 82
Study 7989900 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive multiple risk factor modification programme
Number of subjects: 508
Study 7989900 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 508
Study 4916211 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrronium
Number of subjects: 106
Study 4916211 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hyoscyamine
Number of subjects: 106
Study 4916211 — intervention group
Group type: COMPARATOR
Intervention: Inert tablets (placebo)
Number of subjects: 106
Study 1233216 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (0.06 mg/kg i.v.)
Number of subjects: 0
Study 1233216 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (0.12 mg/kg i.v.)
Number of subjects: 0
Study 1233216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1233216 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprenaline (increasing doses)
Number of subjects: 0
Study 31486684 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with Deferoxamine (DFO) and Deferasirox (DFX)
Number of subjects: 256
Study 31486684 — intervention group
Group type: COMPARATOR
Intervention: Deferoxamine (DFO)
Number of subjects: 256
Study 31486684 — intervention group
Group type: COMPARATOR
Intervention: Deferiprone (DFP)
Number of subjects: 256
Study 31486684 — intervention group
Group type: COMPARATOR
Intervention: Deferasirox (DFX)
Number of subjects: 256
Study 31486684 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy (not specified)
Number of subjects: 256
Study 28303670 — intervention group
Group type: EXPERIMENTAL
Intervention: Z-stitch
Number of subjects: 86
Study 28303670 — intervention group
Group type: COMPARATOR
Intervention: Manual compression
Number of subjects: 86
Study 26195078 — intervention group
Group type: EXPERIMENTAL
Intervention: SSV as LIV (n = 20)
Number of subjects: 54
Study 26195078 — intervention group
Group type: EXPERIMENTAL
Intervention: FLV as LIV (n = 16)
Number of subjects: 54
Study 26195078 — intervention group
Group type: EXPERIMENTAL
Intervention: SSV and FLV as the same vertebra (n = 18)
Number of subjects: 54
Study 26195078 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 54
Study 25205516 — intervention group
Group type: EXPERIMENTAL
Intervention: Neighborhood with moderate median household income (between $36,147 and $53,099)
Number of subjects: 801
Study 25205516 — intervention group
Group type: COMPARATOR
Intervention: Neighborhood with low median household income (<$36,147)
Number of subjects: 801
Study 22713632 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil (μ‐opioid receptor agonist)
Number of subjects: 242
Study 22713632 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 242
Study 21137282 — intervention group
Group type: EXPERIMENTAL
Intervention: Open vertebroplasty combined with short-segmental pedicle screw fixation
Number of subjects: 21
Study 18068589 — intervention group
Group type: EXPERIMENTAL
Intervention: Hawley retainers
Number of subjects: 397
Study 18068589 — intervention group
Group type: COMPARATOR
Intervention: Vacuum-formed retainers (VFRs)
Number of subjects: 397
Study 15890794 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded doses of a selective gonadotropin releasing hormone (GnRH)‐receptor antagonist
Number of subjects: 18
Study 12523577 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithymocyte globulin (ATG) 7.5 to 15 mg/kg
Number of subjects: 160
Study 12523577 — intervention group
Group type: COMPARATOR
Intervention: Control (non-ATG)
Number of subjects: 160
Study 9713561 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced hypocalcaemia (blood ionized calcium lowered by 0.20 mmol/l within 30 min)
Number of subjects: 11
Study 9713561 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced hypocalcaemia followed by a brief return to normocalcaemia (protocol 1)
Number of subjects: 11
Study 9713561 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced hypocalcaemia from the initial hypocalcaemic level of blood ionized calcium (protocol 2)
Number of subjects: 11
Study 9713561 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced hypercalcaemia followed by hypocalcaemia (protocol 3)
Number of subjects: 11
Study 9713561 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial induction of hypocalcaemia and first recovery from hypocalcaemia (protocol 3)
Number of subjects: 11
Study 9713561 — intervention group
Group type: EXPERIMENTAL
Intervention: Second recovery from induced hypocalcaemia (protocol 3)
Number of subjects: 11
Study 8129213 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitolterol mesylate 0.5 to 3.5 mg by continuous-flow nebulization
Number of subjects: 0
Study 8129213 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 2563320 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 180 mg
Number of subjects: 8
Study 2563320 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 100 mg
Number of subjects: 8
Study 2563320 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Terfenadine and Flurbiprofen
Number of subjects: 8
Study 2563320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 4469040 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoramin
Number of subjects: 15
Study 4469040 — intervention group
Group type: COMPARATOR
Intervention: Desipramine (added to indoramin)
Number of subjects: 15
Study 31018221 — intervention group
Group type: COMPARATOR
Intervention: Predictive learning model
Number of subjects: 102
Study 28000180 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone therapy (5-10 g gel/50-100 mg testosterone)
Number of subjects: 48
Study 28000180 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5-10 g gel)
Number of subjects: 48
Study 25583994 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalcetrapib
Number of subjects: 5749
Study 24858152 — intervention group
Group type: EXPERIMENTAL
Intervention: Long regimen: prednisolone 60mg/m²/day for six weeks followed by 40mg/m² every alternate day for six weeks.
Number of subjects: 93
Study 24858152 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen: prednisolone 60mg/m²/day for four weeks followed by 40mg/m² every alternate day for four weeks.
Number of subjects: 93
Study 24858152 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (long and standard regimen)
Number of subjects: 93
Study 22947258 — intervention group
Group type: EXPERIMENTAL
Intervention: High-relevance conducive conditions
Number of subjects: 119
Study 22947258 — intervention group
Group type: EXPERIMENTAL
Intervention: Conducive conditions
Number of subjects: 119
Study 22947258 — intervention group
Group type: EXPERIMENTAL
Intervention: Relevance conditions
Number of subjects: 119
Study 22947258 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeling self-report
Number of subjects: 119
Study 19426995 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA) therapy
Number of subjects: 0
Study 19426995 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17602078 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemotherapy in patients with p27Kip1-negative tumors
Number of subjects: 778
Study 17602078 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemotherapy in patients with p27Kip1-positive tumors
Number of subjects: 778
Study 17602078 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cisplatin-based chemotherapy)
Number of subjects: 778
Study 14988890 — intervention group
Group type: EXPERIMENTAL
Intervention: X‐Press device
Number of subjects: 393
Study 11223497 — intervention group
Group type: EXPERIMENTAL
Intervention: OM‐85 BV
Number of subjects: 0
Study 11223497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9420397 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy for malignancies
Number of subjects: 28
Study 9420397 — intervention group
Group type: COMPARATOR
Intervention: Normal controls (healthy adults)
Number of subjects: 28
Study 9420397 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative skin test and T‐cell population less than 40%
Number of subjects: 28
Study 8213706 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg po metoclopramide (single dose)
Number of subjects: 6
Study 8213706 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg po quid for 7 days
Number of subjects: 6
Study 8213706 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 3628545 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat diet (40% energy from fat)
Number of subjects: 30
Study 3628545 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat diet (20% energy from fat)
Number of subjects: 30
Study 31564177 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone positioning
Number of subjects: 500
Study 31564177 — intervention group
Group type: COMPARATOR
Intervention: Supine positioning
Number of subjects: 500
Study 29404806 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib (600 mg/day; 3 weeks on/1 week off) plus Letrozole (2.5 mg/day; continuous)
Number of subjects: 668
Study 29404806 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus Letrozole
Number of subjects: 668
Study 29404806 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib plus Letrozole
Number of subjects: 668
Study 28762932 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivessel stenting using 2nd generation drug covered stents
Number of subjects: 0
Study 28762932 — intervention group
Group type: EXPERIMENTAL
Intervention: Staged revascularization using 2nd generation drug covered stents
Number of subjects: 0
Study 25612788 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary incentive of $300 offered to participate (incentive group)
Number of subjects: 1314
Study 25612788 — intervention group
Group type: COMPARATOR
Intervention: No monetary incentive offered (no-incentive group)
Number of subjects: 1314
Study 22027932 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diclofenac sodium 0.1% (Voltaren Ophthalmic)
Number of subjects: 42
Study 22027932 — intervention group
Group type: COMPARATOR
Intervention: Topical dexamethasone sodium phosphate 0.1% (Sterodex)
Number of subjects: 42
Study 20097101 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentoalveolar distraction osteogenesis
Number of subjects: 12
Study 18996856 — intervention group
Group type: EXPERIMENTAL
Intervention: Accumulated brisk walking (ten 3-min bouts)
Number of subjects: 15
Study 18996856 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous brisk walking (one 30-min bout)
Number of subjects: 15
Study 18996856 — intervention group
Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 15
Study 17011412 — intervention group
Group type: EXPERIMENTAL
Intervention: Epley maneuver
Number of subjects: 0
Study 17011412 — intervention group
Group type: EXPERIMENTAL
Intervention: Lempert maneuver
Number of subjects: 0
Study 17011412 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients with H‐BPPV
Number of subjects: 0
Study 14616980 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (525 IU daily for 3 months)
Number of subjects: 25
Study 14616980 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 25
Study 11040224 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic modulus (pressure-dependent method)
Number of subjects: 276
Study 11040224 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic and diastolic pressures
Number of subjects: 276
Study 11040224 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta (pressure-independent stiffness index)
Number of subjects: 276
Study 11040224 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial compliance index
Number of subjects: 276
Study 11040224 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta (younger vs older hypertensives)
Number of subjects: 276
Study 11040224 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic modulus (younger vs older hypertensives)
Number of subjects: 276
Study 11040224 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial compliance index (younger vs older hypertensives)
Number of subjects: 276
Study 9582466 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐FU/adrenaline gel
Number of subjects: 319
Study 9582466 — intervention group
Group type: COMPARATOR
Intervention: 5‐FU/adrenaline solution
Number of subjects: 319
Study 9582466 — intervention group
Group type: COMPARATOR
Intervention: 5‐FU gel
Number of subjects: 319
Study 8345231 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified multidrug therapy regimen (rifampicin 600 mg, clofazimine 100 mg, dapsone 100 mg daily for 21 days)
Number of subjects: 30
Study 8345231 — intervention group
Group type: COMPARATOR
Intervention: Standard WHO multidrug regimen (rifampicin 600 mg and clofazimine 300 mg monthly, dapsone 100 mg daily, clofazimine 100 mg on alternate days)
Number of subjects: 30
Study 3578865 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracaine 0.5%/15 mg with 0.2 mg epinephrine
Number of subjects: 60
Study 3578865 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.5%/20 mg without epinephrine
Number of subjects: 60
Study 3578865 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 31504526 — intervention group
Group type: EXPERIMENTAL
Intervention: High Dose (HD) Influenza Vaccine
Number of subjects: 69
Study 31504526 — intervention group
Group type: COMPARATOR
Intervention: Standard Dose (SD) Influenza Vaccine
Number of subjects: 69
Study 28237072 — intervention group
Group type: EXPERIMENTAL
Intervention: Ballena orthotic
Number of subjects: 84
Study 28237072 — intervention group
Group type: COMPARATOR
Intervention: Colditz orthotic
Number of subjects: 84
Study 26822388 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS (Transcutaneous Electrical Nerve Stimulation)
Number of subjects: 60
Study 26822388 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS plus tongue trills
Number of subjects: 60
Study 26822388 — intervention group
Group type: COMPARATOR
Intervention: Control group (15 subjects from EG1 and 15 subjects from EG2)
Number of subjects: 60
Study 25491621 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective retention of the great saphenous vein trunk below the knee
Number of subjects: 280
Study 25491621 — intervention group
Group type: COMPARATOR
Intervention: Stripping the great saphenous vein to the ankle level (Control)
Number of subjects: 280
Study 22737871 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy group (intratyimpanic dexamethasone and basic drug group treatment)
Number of subjects: 90
Study 22737871 — intervention group
Group type: COMPARATOR
Intervention: Basic drug group (ganglioside and vinpocetine injection)
Number of subjects: 90
Study 19437180 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary modification program
Number of subjects: 159
Study 19437180 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity skill development program
Number of subjects: 159
Study 19437180 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of both programs
Number of subjects: 159
Study 18787328 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong intervention
Number of subjects: 120
Study 18787328 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Number of subjects: 120
Study 18787328 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 120
Study 15790946 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate therapy (64 mmol/L per day, continuous intravenous dose, started within 4 days after SAH and continued until 14 days after occlusion of the aneurysm)
Number of subjects: 283
Study 15790946 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate therapy
Number of subjects: 283
Study 11451715 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-fat spread enriched with plant sterol esters (1.1 g/d)
Number of subjects: 224
Study 11451715 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-fat spread enriched with plant sterol esters (2.2 g/d)
Number of subjects: 224
Study 9735936 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (200000 IU for infants > 6 months, 400000 IU for children 1-4 years)
Number of subjects: 0
Study 9735936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8297739 — intervention group
Group type: EXPERIMENTAL
Intervention: CEF + GM-CSF (10 micrograms kg-1 s.c. starting from day 4)
Number of subjects: 62
Study 8297739 — intervention group
Group type: COMPARATOR
Intervention: CEF (cyclophosphamide 600 mg m-2, epidoxorubicin 60 mg m-2 and fluorouracil 600 mg m-2)
Number of subjects: 62
Study 8297739 — intervention group
Group type: EXPERIMENTAL
Intervention: CEF + GM-CSF
Number of subjects: 62
Study 2646253 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative radiation combined with surgery (4,000 cGy delivered to the whole mediastinum and left gastroepiploic lymphatic chain)
Number of subjects: 206
Study 2646253 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 206
Study 2646253 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with lesions showing radiation reaction of grade III
Number of subjects: 206
Study 7975663 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine infusion at a dose of 12.63g in 300 ml of 0.9% NaCl over 90 min
Number of subjects: 4